论文部分内容阅读
肺癌是一种常见的恶性肿瘤,起源于支气管黏膜上皮,占各类型恶性肿瘤的12.3%[1],具有较高的死亡率。肺癌临床治疗方案的选取主要基于早期诊断、组织学分型及临床分期判断,肺癌临床诊断及监控的有效性直接决定了其临床治疗效果。近年来,随着肿瘤分子生物学的发展与应用,多种血清肿瘤标记物成为肺癌诊断与监控的关注重点[2],多种标记物联合动态检测也成为肺癌诊断与治疗监控的重要环节。我
Lung cancer is a common malignant tumor that originates from the bronchial epithelium, accounting for 12.3% of all types of malignancies [1], with a high mortality rate. The selection of clinical treatment options for lung cancer is mainly based on early diagnosis, histological classification and clinical staging. The effectiveness of clinical diagnosis and monitoring of lung cancer directly determines its clinical effect. In recent years, with the development and application of tumor molecular biology, a variety of serum tumor markers have become the focus of diagnosis and monitoring of lung cancer [2]. Combined detection of multiple markers has also become an important link in the diagnosis and treatment of lung cancer. I